FRESENIUS SE+CO.KGAA/ DE0005785604 /
2024-08-30 5:32:11 PM | Chg. +0.05 | Volume | Bid5:32:11 PM | Ask5:32:11 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
33.37EUR | +0.15% | 0 Turnover: - |
-Bid Size: - | -Ask Size: - | 18.73 bill.EUR | - | - |
GlobeNewswire
04-23
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2023-09-04
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
2023-08-31
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
2022-02-25
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
2022-01-05
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
2021-12-31
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
2021-12-09
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-12
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights